In December 2020 COMBACTE-NET’s ARTHR-IS trial concluded patient recruitment. In total 130 cases and 386 controls were included. The team finished the data analysis for all objectives and received interesting results: several risk factors and predictors of treatment failure for S. aureus - prosthetic joint infections (PJI) were identified.
Since an increase in prosthetic joint infections is expected in the next decade in parallel with the increase in the number of hip and knee arthroplasties performed, identifying the risk factors associated with PJI is a major concern in terms of global health. ARTHR-IS’s aim is to determine the risk factors associated with S. aureus-PJI, the healthcare utilisation and the incidence and the predictors of treatment failure of S. aureus-PJI after a primary hip and knee arthroplasty.
The information obtained within the trial, will help the design of preventive measures and improve the medical prognosis of this disease. The team collected key information on the incidence and use of healthcare resources to calculate the global burden of prosthetic infection due to S. aureus.
The results on the identified risk factors of S. aureus- PJI were presented at the last ECCMID congress with very good feedback. In addition, the first manuscript of the project has been submitted to a specialized international journal. The first ARTHR-IS results are expected to be published soon.
Due to the ageing population, the number of arthroplasties is expected to grow over the coming years. S. aureus is a primary cause of prosthesis joint infection with serious consequences. This microorganism is frequently associated with treatment failure, hospitalizations and the need of prosthesis removal, leading to an important morbidity and an increase in healthcare costs.
ARTHR-IS (arthroplasty infections due to Staphylococcus aureus) is a case-control study aiming to provide estimates of the rate of SA-PJI, hospitalizations and surgical procedures related to SA-PJI, predictors for such infections and the factors influencing therapeutic failure and quantifying the additional costs. The results will help the design of future clinical trials to prevent SA-PJI prosthesis infection by providing reliable estimates on the incidence of SA-PJI and the subsequent burden on health care services.
This ARTHR-IS trial is a collaborative initiative between the Hospital Virgen Macarena in Sevilla and GlaxoSmithKline as academic and EFPIA partners respectively.